Carol Mack v. Stryker Corporation
748 F.3d 845
8th Cir.2014Background
- Carol Mack underwent arthroscopic shoulder surgery in August 2002; a Stryker-manufactured continuous pain pump delivering bupivacaine into the glenohumeral (intra-articular) joint was used.
- Postoperatively Mack developed glenohumeral chondrolysis and later sued Stryker for negligence and strict products liability (design defect and failure to warn); her husband asserted loss of consortium.
- The district court granted summary judgment for Stryker, concluding that, based on medical literature available in 2002, the risk of cartilage damage from intra‑articular continuous anesthetic infusion was not objectively foreseeable and therefore Stryker had no duty to warn.
- Mack appealed, relying principally on expert Dr. Stephen Trippel, who cited 12 pre‑2002 studies (animal studies, irrigation solution studies, some case reports) to argue manufacturers should have foreseen cartilage harm from continuous intra‑articular infusion.
- The court reviewed the literature de novo and held the cited studies either involved non‑anesthetic solutions, transient/reversible effects, or were outweighed by contemporaneous literature endorsing intra‑articular pump use; thus the specific danger was not objectively foreseeable in 2002.
- The court also rejected Mack’s argument that prior FDA §510(k) denials for intra‑articular clearance put Stryker on notice, explaining §510(k) equivalence rejections do not signify a safety determination per Medtronic v. Lohr.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Stryker could reasonably foresee that continuous intra‑articular infusion of bupivacaine posed a risk of chondrolysis in 2002 | Mack: Dr. Trippel’s literature review showed sufficient pre‑2002 evidence (animal studies, irrigant harms, case reports) to put a manufacturer on notice | Stryker: Pre‑2002 literature did not show a link between intra‑articular anesthetic pumps and chondrolysis; many studies involved different solutions or showed reversible effects; some contemporaneous studies endorsed pump safety | Held for Stryker: the cited literature did not objectively forewarn of the specific danger; foreseeability was not established as a matter of law |
| Whether expert testimony (Dr. Trippel) created a genuine factual dispute about foreseeability | Mack: Expert interpretation of literature raised a fact question for the jury | Stryker: Expert relied on studies that do not support his causation/foreseeability conclusions; district court properly assessed literature | Held for Stryker: court concluded the underlying articles did not support Dr. Trippel’s opinion so no triable issue remained |
| Whether FDA §510(k) denials put Stryker on notice to test or warn about intra‑articular use | Mack: Denials meant no predicate device existed and signaled lack of proven safety, triggering duty to test/warn | Stryker: §510(k) refusals concern equivalence, not safety; denials did not convey safety concerns and did not impose extra duties | Held for Stryker: Medtronic controls; §510(k) focuses on equivalence, so denials did not establish foreseeability or a duty to warn |
| Appropriateness of summary judgment standard application | Mack: District court misapplied summary judgment by discounting expert and construing facts for Stryker | Stryker: Court applied law correctly and viewed evidence in record context | Held for Stryker: reviewing court affirms de novo; viewing evidence in light favoring Mack still yields no genuine issue because literature does not reasonably forewarn |
Key Cases Cited
- Lee v. Crookston Coca‑Cola Bottling Co., 188 N.W.2d 426 (Minn. 1971) (elements of strict products liability)
- Bilotta v. Kelley Co., Inc., 346 N.W.2d 616 (Minn. 1984) (manufacturer’s duty to exercise reasonable care in design and foreseeability test)
- O'Hare v. Merck & Co., 381 F.2d 286 (8th Cir. 1967) (manufacturer duty to investigate based on foreseeable medical knowledge)
- Whiteford by Whiteford v. Yamaha Motor Corp., U.S.A., 582 N.W.2d 916 (Minn. 1998) (foreseeability determines duty to warn; objective‑reasonableness standard)
- Domagala v. Rolland, 805 N.W.2d 14 (Minn. 2011) (foreseeability is a threshold issue for court; submit to jury only in close cases)
- Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996) (§510(k) equivalence process addresses equivalence not safety)
- Rodriguez v. Stryker Corp., 680 F.3d 568 (6th Cir. 2012) (similar analysis rejecting expert’s literature‑based foreseeability theory and affirming summary judgment for manufacturer)